Altimmune (NASDAQ:ALT) Issues Earnings Results, Beats Expectations By $0.03 EPS

Altimmune (NASDAQ:ALT) posted its quarterly earnings results on Tuesday. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.03, Zacks reports. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 52.60%. The firm had revenue of $0.01 million for the quarter. During the same quarter last year, the firm posted ($0.39) EPS.

Altimmune Trading Down 11.2 %

NASDAQ ALT traded down $1.06 during trading on Thursday, reaching $8.46. The company’s stock had a trading volume of 5,127,731 shares, compared to its average volume of 3,864,876. The stock has a market capitalization of $600.91 million, a PE ratio of -5.45 and a beta of 0.09. The business has a 50-day moving average price of $6.99 and a 200-day moving average price of $6.90. Altimmune has a 1-year low of $2.34 and a 1-year high of $14.84.

Insider Buying and Selling at Altimmune

In other news, Director David Drutz sold 16,011 shares of the business’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of $6.90, for a total value of $110,475.90. Following the completion of the sale, the director now directly owns 41,958 shares in the company, valued at approximately $289,510.20. The trade was a 27.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 4.10% of the company’s stock.

Analyst Upgrades and Downgrades

ALT has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Altimmune in a report on Thursday. B. Riley reissued a “buy” rating and issued a $20.00 target price on shares of Altimmune in a research report on Monday, August 12th. UBS Group began coverage on shares of Altimmune in a research report on Tuesday. They issued a “buy” rating and a $26.00 target price on the stock. Finally, Evercore ISI raised shares of Altimmune to a “strong-buy” rating in a research report on Friday, August 9th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $20.00.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.